Want to see NUVB full AI Analyst Report?
NUVB Stock Chart & Stats
$5.08
-$0.19(-5.85%)
At close: 4:00 PM EST
$5.08
-$0.19(-5.85%)
Day’s Range― - ―
52-Week Range$2.18 - $9.75
Previous CloseN/A
Volume977.37K
Average Volume (3M)7.76M
Market Cap
$2.03B
Enterprise Value$1.30K
Total Cash (Recent Filing)$533.73M
Total Debt (Recent Filing)$9.83M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding348,201,970
10 Day Avg. Volume5,862,147
30 Day Avg. Volume7,763,211
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.00Price Target Upside175.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$201.44M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And High Gross MarginRapid top-line growth with roughly 91.6% gross margin indicates attractive unit economics and expanding commercial traction. Durable high gross margins support scalable profitability as volumes rise, enabling reinvestment in R&D and commercialization while improving long-term cash conversion if operating losses can be reduced.
Differentiated Clinical Profile And Guideline InclusionGuideline inclusion and strong CNS responses create sustainable clinical differentiation in ROS1 NSCLC, improving prescribing durability and reimbursement prospects. Durable efficacy (long DOR/PFS) supports higher on-therapy durations and predictable lifetime value per patient, bolstering long-term commercial positioning.
Robust Liquidity And Capital Structure ActionsLarge cash balance plus a recent long-dated convertible issuance and retirement of secured debt materially extend runway and reduce near-term leverage risk. This durable liquidity cushions operations and clinical programs, allowing execution of launch and trials without immediate refinancing, though convertibles imply future dilution risk.
Bears Say
Sustained Cash Burn And Negative Free Cash FlowPersistent negative operating cash flow and declining free cash flow indicate ongoing structural cash burn to fund launch and R&D. Over a multi-quarter horizon this creates reliance on financing or milestones, constraining flexibility and risking dilution if product revenue growth doesn't quickly offset spend.
Large Operating Losses And Negative Returns On EquityMaterial and persistent operating losses produce negative ROE and can erode equity over time if uncorrected. Such structural unprofitability increases operational risk, limits internal capital generation, and heightens dependence on external funding until product revenues sustainably cover overhead.
Near-Term Revenue Reliance On Collaboration MilestonesA meaningful share of recent revenue derived from an upfront Eisai payment and contingent milestones, creating timing and realization risk. Structural dependence on non-recurring collaboration payments can mask underlying product sales trends and produce revenue volatility until sustained, repeatable product sales dominate.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio Inc’s price range in the past 12 months?
Nuvation Bio Inc lowest stock price was $2.18 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio Inc’s market cap?
Nuvation Bio Inc’s market cap is $2.03B.
When is Nuvation Bio Inc’s upcoming earnings report date?
Nuvation Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were Nuvation Bio Inc’s earnings last quarter?
Nuvation Bio Inc released its earnings results on May 04, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.038.
Is Nuvation Bio Inc overvalued?
According to Wall Street analysts Nuvation Bio Inc’s price is currently Undervalued.
Does Nuvation Bio Inc pay dividends?
Nuvation Bio Inc does not currently pay dividends.
What is Nuvation Bio Inc’s EPS estimate?
Nuvation Bio Inc’s EPS estimate is -0.14.
How many shares outstanding does Nuvation Bio Inc have?
Nuvation Bio Inc has 348,201,970 shares outstanding.
What happened to Nuvation Bio Inc’s price movement after its last earnings report?
Nuvation Bio Inc reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Nuvation Bio Inc?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (175.59% Upside)
$14.00 (175.59% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $118.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.92%
12-Months-Change
Fundamentals
Return on Equity
-44.10%
Trailing 12-Months
Asset Growth
23.91%
Trailing 12-Months
Company Description
Nuvation Bio Inc
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
NUVB Stock 12 Month Forecast
Average Price Target
$14.00
▲(175.59% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
24.84% Insiders
15.76% Mutual Funds
0.34% Other Institutional Investors
47.95% Public Companies and Individual Investors